Ardelyx (NASDAQ:ARDX) Cut to Outperform at Raymond James
Raymond James cut shares of Ardelyx (NASDAQ:ARDX – Free Report) from a strong-buy rating to an outperform rating in a research note issued to investors on Friday, MarketBeat.com reports. Raymond James currently has $11.00 price objective on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on ARDX. Piper Sandler upgraded shares […]
Raymond James cut shares of Ardelyx (NASDAQ:ARDX – Free Report) from a strong-buy rating to an outperform rating in a research note issued to investors on Friday, MarketBeat.com reports. Raymond James currently has $11.00 price objective on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on ARDX. Piper Sandler upgraded shares […]
